The Association of Polymorphisms in Nrf2 and Genes Involved in Redox Homeostasis in the Development and Progression of Clear Cell Renal Cell Carcinoma

Table 6

Nrf2, SOD2, GPX1, and GSTP1 polymorphisms as predictors for overall mortality in patients with ccRCC.

Model 1^a		Model 2^b
HR (95% CI)	value	HR (95% CI)	value
Risk for overall mortality comparing Nrf2-variant^c genotype to Nrf2-reference^d-type genotype carriers
1.030 (0.579–1.833)	0.919	1.104 (0.456–2.674)	0.826
Risk for overall mortality comparing SOD2-variant^e genotype to SOD2-reference^f-type genotype carriers
1.290 (0.676–2.461)	0.440	1.687 (0.494–5.755)	0.404
Risk for overall mortality comparing GPX1-variant^g genotype to GPX1-reference^h-type genotype carriers
0.737 (0.462–1.177)	0.201	1.388 (0.654–2.946)	0.393
Risk for overall mortality comparing GSTP1-variant^i genotype to GSTP1-reference^j-type genotype carriers
1.627 (0.664–3.986)	0.287	3.897 (0.681–22.304)	0.126

^aModel 1 adjusted for age and gender; ^bmodel 2 adjusted for the covariates from model 1 and recognized risk factors for ccRCC development (pack-years, BMI, and hypertension); ^cNrf2-variant-type genotype—C/A+A/A; ^dNrf2-reference genotype—C/C; ^eSOD2 variant-type genotype—Ala/Val+Val/Val; ^fSOD2 reference genotype—Ala/Ala; ^gGPX1-variant-type genotype—Pro/Leu+Leu/Leu; ^hGPX1-reference genotype—Pro/Pro; ⁱGSTP1-variant-type genotype—combination of genotypes of rs1695 and rs1138272 SNPs (Ile/Val+Val/Val) (Ala/Val+Val/Val); ^jGSTP1-reference genotype—combination of reference genotypes of both rs1695 and rs1138272 (Ile/Ile) (Ala/Ala); HR: hazard ratio; CI: confidence interval.